Dong Mengting, Jiang Su, Tian Wenyan, Yan Ye, Gao Chao, Gao Jinping, Sheng Yan, Wang Yingmei, Xue Fengxia
a Department of Obstetrics and Gynaecology , Tianjin Medical University General Hospital , Tianjin , China.
Cancer Biol Ther. 2018;19(11):956-961. doi: 10.1080/15384047.2018.1456609. Epub 2018 May 3.
: Endometrial cancer (EC) occurs most commonly after menopause. A proportion of patients present with advanced age and comorbidities, and become ineligible for surgery. The optimal treatment strategy of these patients remains a clinical challenge. Aromatase inhibitor (AI) combined with Gonadotropin-releasing hormone agonist (GnRH-a) possesses profound effect in suppressing the estrogen level, has become a valid treatment in the breast cancer. However, the combined use of an AI and a GnRH-a in EC has rarely been studied. : Herein, we report the combination of an AI and a GnRH-a in the treatment of three patients with advanced age or comorbidities who were ineligible for surgery. The disease remained stable for two years in patients who received the combination treatment as an initial approach without any adverse effects. Moreover, an AI combined with a GnRH-a also effective as salvage treatment of recurrent patients. Further, we provide a brief review of the literature. : The combination of an AI and a GnRH-a presents satisfactory therapeutic effect and provides an optimal option for inoperable EC patients.
子宫内膜癌（EC）最常见于绝经后。一部分患者年龄较大且伴有合并症，不适合进行手术。这些患者的最佳治疗策略仍然是一个临床挑战。芳香化酶抑制剂（AI）联合促性腺激素释放激素激动剂（GnRH-a）在抑制雌激素水平方面具有显著效果，已成为乳腺癌的有效治疗方法。然而，AI与GnRH-a在EC中的联合应用很少被研究。在此，我们报告AI与GnRH-a联合用于治疗三名因年龄较大或合并症而不适合手术的患者。接受联合治疗作为初始方法的患者疾病稳定了两年，且无任何不良反应。此外，AI与GnRH-a联合作为复发患者的挽救治疗也有效。此外，我们对文献进行了简要综述。AI与GnRH-a联合应用呈现出令人满意的治疗效果，为无法手术的EC患者提供了一个最佳选择。
